The antiserum was produced against synthesized peptide derived from human eNOS around the phosphorylation site of Ser615. AA range:581-630

Phospho-NOS3 (S615) Polyclonal Antibody detects endogenous levels of NOS3 protein only when phosphorylated at S615.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):FNsIS

NOS3

Nitric oxide synthase endothelial

NOS3 ;
Nitric oxide synthase ;
endothelial ;
Constitutive NOS ;
cNOS ;
EC-NOS ;
Endothelial NOS ;
eNOS ;
NOS type III ;
NOSIII

Nitric oxide is a reactive free radical which acts as a biologic mediator in several processes, including neurotransmission and antimicrobial and antitumoral activities. Nitric oxide is synthesized from L-arginine by nitric oxide synthases. Variations in this gene are associated with susceptibility to coronary spasm. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009],

Catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+).,cofactor:Binds 1 FAD.,cofactor:Binds 1 FMN.,cofactor:Heme group.,cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme.,enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN.,Function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.,online information:Nitric oxide synthase entry,polymorphism:Variation in NOS3 seem to be associated with susceptibility to coronary spasm.,similarity:Belongs to the NOS family.,similarity:Contains 1 FAD-binding FR-type domain.,similarity:Contains 1 flavodoxin-like domain.,subcellular location:Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity.,subunit:Homodimer. Interacts with NOSIP and NOSTRIN.,tissue specificity:Platelets, placenta, liver and kidney.,

Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity.

Platelets, placenta, liver and kidney.

>>Arginine biosynthesis ;
>>Arginine and proline metabolism ;
>>Metabolic pathways ;
>>Calcium signaling pathway ;
>>cGMP-PKG signaling pathway ;
>>HIF-1 signaling pathway ;
>>Sphingolipid signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>VEGF signaling pathway ;
>>Apelin signaling pathway ;
>>Platelet activation ;
>>Estrogen signaling pathway ;
>>Oxytocin signaling pathway ;
>>Relaxin signaling pathway ;
>>Insulin resistance ;
>>AGE-RAGE signaling pathway in diabetic complications ;
>>Diabetic cardiomyopathy ;
>>Lipid and atherosclerosis ;
>>Fluid shear stress and atherosclerosis